OneThree Biotech United States

My organization, OneThree Biotech, is a company that is dedicating our biology-driven AI expertise towards the fight against cancer. We’re combining systems biology with artificial intelligence to uncover new insights and build the next generation of drug discovery. We’ve built 14 different algorithms into our platform to provide insights across steps like target selection, compound mechanisms, toxicity and metabolism, and patient biomarkers at the beginning of the development process. This not only provides greater mechanistic insights, but also helps ensure a greater success rate for drugs entering preclinical development. Over the course of 2020 our founders have spoken at countless events like the BioData World Congress, Pharma and Patient USA, and various Reuters events culminating in our most recent accomplishment of winning Reuters' Entrepreneur Award for Health Solutions.
Company Size (Fulltime employees)
Please specify your partnering goal
To generate new insights to accelerate our partner's internal R&D or identify new candidates to fill partner's pipeline. Together we can discover new medicines at an unprecedented scale.
Headquartner in China
Mr. Abhinav Subramaniam
Strategy and Operations Associate 
Functionality

Otomagnetics United States

Otomagnetics is a biotechnology Company developing a non-invasive platform technology to deliver drugs and other therapeutic payloads to the inner and middle ear compartments, eye and skin. The link to the explainer video on the technology is provided below.

https://www.youtube.com/watch?v=1go9HYjMlFk&feature=youtu.be
Company Size (Fulltime employees)
Year of foundation
2012
Please specify your partnering goal
Looking for partners focusing on ear disorders, macular degeneration and diabetic ulcers
Headquartner in China
Mrs. Abhita Batra
CEO 
Functionality

Panakes Partners SGRSpa Italy

Panakes Partners is a Venture Capital investor financing early and late stage medical companies, with innovative products and great ambition teams.
Panakes invests in seed to pre-IPO rounds mainly in European companies but also in Israel and in the US.
The team provides more than capital working together with entrepreneurs to develop successful businesses as an active and well-connected investor. Panakes has a strong relationships with selected industrial partners of the sector to help companies to accelerate their development
Website:
www.panakes.it
Company Size (Fulltime employees)
Year of foundation
2015
Please specify your partnering goal
to see companies
Headquartner in China
Medtech Category
Mrs. Diana Saraceni
Partner 

PepGene Inc United States

Cancer Immunotherapy development
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Tenghui Chen
CTO 

Phagelux China

Phagelux is creating novel and best in class biological skin sciences products.
Company Size (Fulltime employees)
Year of foundation
2015
Please specify your partnering goal
Global partners
Headquartner in China
Mr. Mark Engel
Chairman 
Functionality

Pharma - Acon Pharma United States

Please contact us using Acon Pharmaceutical Inc. 

Headquartner in China
Yuan Xudong
CEO 
Functionality

Phoenix wealth United States

Phoenix wealth provides access to investors to invest into siruptive technology during pre-seed or seed stages.
Website:
Phoenixwealth.ae
Company Size (Fulltime employees)
Please specify your partnering goal
Invest and grow
Headquartner in China
Mr. Sai Kunnath
Ceo 
Functionality

PhysioCue United States

PhysioCue is digital health and therapy device development company, has developed a non-invasive hypertension therapy device and a migraine and headache therapy device and migraine and headache pain monitoring mobile app. Using our device once daily for 5-minute treatments gradually elongated the reduced blood pressure. PhysioCue's therapy devices are efficient, safe, easy to use, and has none of the side effects associated with drugs. We have manufactured our devices and delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices. PhysioCue devices can help people and save lives.

Company Size (Fulltime employees)
Year of foundation
2014
Headquartner in China
Medtech Category
Medtech Information 1
Thermal neurostimulation technology for a non-invasive hypertension therapy device
Slides Deck
(pdf, 6.11MB)
Simon Yi
LinkedIn logo President 
Functionality

Phyteau United States

Phyteau is developing an innovative, new class of therapeutics for diabetes, obesity, related conditions like NAFLD, NASH and prediabetes, and weight-loss. Unlike many drugs in the market today, our therapeutics are completely safe, and free of adverse side-effects.

Phyteau’s new incretin-based approach activates the body’s natural metabolic system
by triggering specialized enteroendocrine cells in the lining of the intestines to release
therapeutic levels of key hormones, including GLP-1, PYY and CCK. These boosted hormones:

1) signal insulin release,
2) reduce blood sugar levels and peaks, and HbA1c,
3) reduce appetite, food intake and weight, increase satiety,
4) slows gastric emptying and intestinal motility,
5) improve metabolism and fat thermogenesis,
6) reduce liver fat and fibrosis,
7) protect against many age-related functional declines and conditions, and
8) provide restorative and protective benefits to the cardiovascular and nervous systems and major organs

The result is safe and affordable first-line treatments that provide a powerful tool for blood sugar control, weight-loss and improving metabolism. Our technology, developed at Caltech, UCLA and Cedars Sinai Medical Center, has 3 patents awarded, 5 more pending, with more planned.

Phyteau’s deep technology platform and portfolio of agents allows us to address growing unmet global needs in a variety of markets. We have 3 pharmaceutical products in development as well as breakthrough medical and functional food products and other consumer health & nutrition products.

Year of foundation
2017
Headquartner in China
Assets Information 1
Phyteau's therapeutic platform represents a comprehensive range of gut hormone secretagogues. Our gut hormone secretagogues are powerful agonists for GCPR's on enteroedocrine cells in the intestines, causing the therapeutic release of metabolic gut hormones (including GLP-1, PYY and CCK).
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 294.95KB)
Bonn Macy
CEO 
Functionality

Pleiogenix United States

Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial disease that Pleiogenix is targeting is alcoholic hepatitis (AH), with additional diseases to follow (COVID-19, Fibrosis, and NASH) . AH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. The global and US prevalence is 20-25%. The AH market is estimated to be $1.2 Billion in 2025, having a current annual growth rate of 6% (2019-2025). There are no approved efficacious therapeutics for the prevention or treatment of AH (dexamethasone reduces inflammation). The target patients for therapy include those with moderate and severe forms of AH. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic, and multiple metabolic clinical benefits. In patients suffering from AH, inflammation is severely increased. In animal models of NASH, increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical that exhibits multiple beneficial effects, in the context of AH.
Company Size (Fulltime employees)
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Fundraising (Seed Round)
Headquartner in China
Assets Information 1
PLG888|Orally-available, Phase 2A-ready drug candidate|alcoholic hepatitis|7 US patents; 1 each for Japan, Great Britain, France, Germany, and Australia
Assets Information 2
PLG888|ailable, Phase 2A-ready drug candidate|COVID-19; prevent /reduce cytokine storm|7 US patents; 1 each for Japan, Great Britain, France, Germany, and Australia
Assets Information 3
PLG888|Orally-available, Phase 2A-ready drug candidate|non-alcoholic steatohepatitis (NASH); Fibrosis diseases|7 US patents; 1 each for Japan, Great Britain, France, Germany, and Australia
Biotech/Pharma Asset Stage
Dr. Joseph Evans
CEO & President 
Functionality